Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · Real-Time Price · USD

1.160

+0.040 (3.57%)

May 8, 2025, 4:00 PM - Market closed

Estrella Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	3.14	3.2	0.66	0.3	0.28
Research & Development	5.72	4.11	10.45	1.39	0.46
Operating Expenses	8.85	7.31	11.11	1.69	0.73
Operating Income	-8.85	-7.31	-11.11	-1.69	-0.73
Pretax Income	-8.85	-7.31	-11.11	-1.69	-0.73
Income Tax Expense	0	0	-	-	-
Net Income	-8.85	-7.31	-11.11	-1.69	-0.73
Preferred Dividends & Other Adjustments	-	-	-	-0.61	-
Net Income to Common	-8.85	-7.31	-11.11	-1.07	-0.73
Shares Outstanding (Basic)	37	27	0	-	-
Shares Outstanding (Diluted)	37	27	0	-	-
Shares Change (YoY)	34.73%	8764.81%	-	-	-
EPS (Basic)	-0.24	-0.27	-36.35	-	-
EPS (Diluted)	-0.24	-0.27	-36.35	-	-
EBIT	-8.85	-7.31	-11.11	-1.69	-0.73

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q